Research

Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone (GH) treatment in short prepubertal children

Björn Andersson¹ , Gunnel Hellgren¹ , Andreas FM Nierop² , Ze'ev Hochberg³ and Kerstin Albertsson-Wikland¹

¹  Göteborg Pediatric Growth Research Center, Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden

²  Muvara bv, Leiderdorp, The Netherlands

³  Meyer Children's Hospital, Rambam Medical Center and Rappaport Faculty of Medicine and Research Institute, Technion - Israel Institute of Technology, Haifa, Israel

author email corresponding author email

Proteome Science 2009, 7:40doi:10.1186/1477-5956-7-40

Published:	2 November 2009

Abstract

Background

The broad range in growth observed in response to growth hormone (GH) treatment is mainly caused by individual variations in both GH secretion and GH sensitivity. Individual GH responsiveness can be estimated using evidence-based models that predict the response to GH treatment; however, these models can be improved. High-throughput proteomics techniques can be used to identify proteins that may potentially be used as variables in such models in order to improve their predictive ability. Previously we have reported that proteomic analyses can identify biomarkers that discriminate between short prepubertal children with idiopathic short stature (ISS) who show good or poor growth in response to GH treatment. In this study we used a pharmaco-proteomic approach to identify novel factors that correlate with the growth response to GH treatment in prepubertal children who are short due to GH deficiency or ISS. The study included 128 short prepubertal children receiving GH treatment, of whom 39 were GH-deficient and 89 had ISS. Serum protein expression profiles at study start and after 1 year of GH treatment were analyzed using SELDI-TOF. Cross-validated regression and random permutation analyses were performed to identify significant correlations between protein expression patterns and the 2-year growth response to GH treatment.

Results

At start of treatment we identified a combination of seven protein peaks that correlated with the 2-year growth response in the GH-deficient group (R² = 0.73). After 1 year of treatment, a combination of four peaks in the GH-deficient group (R² = 0.64), eight peaks in the ISS group R² = 0.47) and eight peaks in the total study group correlated with the 2-year growth response R² = 0.38).

The peaks identified corresponded to apolipoproteins A-I, A-II, C-I, C-III, transthyretin and serum amyloid A 4, which are all part of the high-density lipoprotein.

Conclusion

Using a proteomic approach we identified biomarkers related to the lipoprotein profile that could be used to predict growth response to GH treatment in prepubertal children who are short as a result of GH-deficiency or who have ISS.

These results support our previous findings that apolipoproteins and transthyretin may have a role in GH sensitivity.